32 Breast Cancer Clinical Trials in Chicago, IL (2026)

Q: How do I join a clinical trial in Chicago?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you.

Recruiting Breast Cancer Studies in Chicago

NCT02620852Recruiting

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended t...

Chicago, ILNA100,000 participantsUniversity of California, San Francisco

View Study Details

NCT00898131Recruiting

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

RATIONALE: Collecting and storing samples of tumor tissue from patients with breast cancer to study in the laboratory may help doctors learn more about cancer. PURPOSE: This phase I study is collecti...

Chicago, IL10,000 participantsNorthwestern University

View Study Details

NCT06401421Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for cir...

Chicago, IL1,800 participantsExact Sciences Corporation

View Study Details

NCT05841355Recruiting

MADRE (Mammograms Available Due to Research and Education)

The design builds on past studies by integrating social network analysis (SNA) and implementation science (IS) into a longitudinal randomized clinical trial (RCT). The investigator will compare the lo...

Chicago, ILNA600 participantsUniversity of Illinois at Chicago

View Study Details

NCT05483283Recruiting

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Ai...

Chicago, ILNA600 participantsUniversity of Illinois at Chicago

View Study Details

NCT03729115Recruiting

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women....

Chicago, ILNA400 participantsUniversity of Chicago

View Study Details

NCT06075953Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effe...

Chicago, ILPHASE2400 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT06253871Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that...

Chicago, ILPHASE1383 participantsIambic Therapeutics, Inc

View Study Details

NCT05377996Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors...

Chicago, ILPHASE1360 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06533826Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan fol...

Chicago, ILPHASE2357 participantsAna C Garrido-Castro, MD

View Study Details

NCT05683418Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study e...

Chicago, ILPHASE1241 participantsTotus Medicines

View Study Details

NCT06099769Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor...

Chicago, ILPHASE2201 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05467891Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast can...

Chicago, ILPHASE2200 participantsOana Danciu

View Study Details

NCT06184750Recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well establi...

Chicago, ILPHASE2200 participantsNational Cancer Institute (NCI)

View Study Details

NCT06062498Recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent b...

Chicago, ILPHASE2174 participantsNorthwestern University

View Study Details

NCT05868226Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patie...

Chicago, ILPHASE1124 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT06764940Recruiting

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastas...

Chicago, ILPHASE2120 participantsBiostar Pharma, Inc.

View Study Details

NCT04468061Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts ...

Chicago, ILPHASE2110 participantsDana-Farber Cancer Institute

View Study Details

NCT04841148Recruiting

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor dissemin...

Chicago, ILPHASE296 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT05941520Recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for pa...

Chicago, ILPHASE280 participantsNational Cancer Institute (NCI)

View Study Details

NCT06908928Recruiting

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-...

Chicago, ILPHASE152 participantsMabwell (Shanghai) Bioscience Co., Ltd.

View Study Details

NCT06169371Recruiting

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) Aft...

Chicago, ILPHASE450 participantsUniversity of Illinois at Chicago

View Study Details

NCT04434040Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

Chicago, ILPHASE240 participantsDana-Farber Cancer Institute

View Study Details

NCT04891068Recruiting

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first ...

Chicago, ILPHASE240 participantsUniversity of Illinois at Chicago

View Study Details

NCT05259410Recruiting

Time Restricted Eating During Chemotherapy for Breast Cancer

Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment. Pre-clinical murine studies report intermittent fasting increases effe...

Chicago, ILNA40 participantsUniversity of Illinois at Chicago

View Study Details

NCT07387445Recruiting

Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.

This study is being done to better understand how time restricted eating (eating all food in an 8 hour window) can help a person receiving chemotherapy treatment for breast cancer, stages I-IV. The ai...

Chicago, ILNA40 participantsUniversity of Illinois at Chicago

View Study Details

NCT03990896Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation....

Chicago, ILPHASE230 participantsMassachusetts General Hospital

View Study Details

NCT05029999Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil...

Chicago, ILPHASE130 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT04886531Recruiting

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combinat...

Chicago, ILPHASE230 participantsRuth O'Regan

View Study Details

NCT06441890Recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncolog...

Chicago, ILPHASE228 participantsUniversity of Illinois at Chicago

View Study Details

NCT06085742Recruiting

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy....

Chicago, ILPHASE225 participantsUniversity of Illinois at Chicago

View Study Details

NCT04427293Recruiting

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will recei...

Chicago, ILPHASE112 participantsUniversity of Illinois at Chicago

View Study Details

About Breast Cancer Clinical Trials in Chicago

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 32 breast cancer clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 116,863 participants. Research is being sponsored by University of California, San Francisco, Northwestern University, Exact Sciences Corporation and 17 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Chicago — FAQ

Are there breast cancer clinical trials in Chicago?

Yes, there are 32 breast cancer clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 32 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 16, 2026 from ClinicalTrials.gov